
lower ep outlook robust
follow abt call tweak ep estim
due roughli ep headwind
face fx given abt robust emphasi high end revenu growth
outlook next year see much risk abt forward earn
multipl abt balanc sheet time net leverag believ
buyback could protect earn currenc worsen bottom line see
durabl growth stori abl compound ep even
fx move reiter buy rate
product level detail notabl
freestyl libr revenu growth patient volum number
stand view think bode well next sever year
patient use libr us
mitraclip revenu grew help recent data set
expect happen earnest
portico revenu confirm revenu
slightli growth flat pacer growth
abt neuromodul total revenu notabl weak spot abt
robust abt us spinal cord stim revenu slightli
view neutral read
abt stent sale abt heartmat lvad sale
emerg market growth devic sale
bode especi well view
full definit iqmethod sm measur see page
bofa merril lynch seek busi issuer cover research report
result investor awar firm may conflict interest could
affect object report investor consid report singl
factor make invest decis
refer import disclosur page analyst certif page price object
basis/risk page
net dbt
return capit employ
return equiti
iqmethod sm qualiti earn
net incom cont oper
chang work capit
full definit iqmethod sm measur see page
lead diversifi global
healthcar compani develop manufactur
market brand gener medic devic
nutrit product diagnost solut
expect continu grow underli
earn double-digit rang organ
basi next sever year plu addit
growth deal accret think given growth
profil least trade line
higher multipl med-tech peer
tabl medic devic busi total organ growth
million
tabl ex rf drg deep brain
tabl ex rf drg deep brain
million
million
point diagnost
tabl estim organ growth requir meet consensu estim
po base price-to-earnings multipl premium peer
trade believ justifi base growth rate potenti
upsid organ pipelin new product
downsid risk po lower-than-expect growth emerg market
increas competit pressur profit margin lighter-than-expect
healthcar util price pressur inabl close success integr
deal unfavor fx move
bob hopkin herebi certifi view express research report accur
reflect person view subject secur issuer also certifi
part compens directli indirectli relat specif
recommend view express research report
becton dickinson compani
qualiti earn
iqmethod smi set bofa merril lynch standard measur serv maintain global consist three broad head busi perform qualiti earn valid key featur
iqmethod consist structur detail transpar methodolog guidelin maxim effect compar valuat process identifi common pitfal
iqdatabas real-tim global research databas sourc directli equiti analyst earn model includ forecast well histor data incom statement balanc sheet cash
flow statement compani cover bofa merril lynch
iqprofil sm iqmethod sm servic mark america corpor iqdatabas regist servic mark america corpor
